IL6 and congenital rubella syndrome: The mainstay of CRS therapy has been the selective blockade of IL-6 signaling by tocilizumab (IL-6 receptor antagonist) or siltuximab (chimeric anti-IL-6 mAb), which results in rapid resolution of CRS symptoms, usually within a few hours.